TYK Medicines-B (02410) to Issue 76 Million Subscription Shares to Qilu and CVG Global

Stock News11-12

TYK Medicines-B (02410) has announced that on November 12, 2026, the company entered into separate subscription agreements with the subscribers (Qilu and CVG Global), pursuant to which Qilu and CVG Global have conditionally agreed to subscribe, and the company has conditionally agreed to allot and issue, 57 million H shares and 19 million H shares to Qilu and CVG Global respectively at a subscription price of HK$3.80 per subscription share.

The subscription price of HK$3.80 represents a discount of approximately 7.32% to the closing price of HK$4.100 per H share as quoted on the Stock Exchange on November 12, 2026 (being the last trading day).

The gross proceeds from the subscription amount to HK$288.8 million. After deducting professional fees and other related expenses payable by the company in respect of the subscription, the net proceeds from the subscription are approximately HK$288 million (equivalent to approximately RMB 247 million).

Approximately 60% of the net proceeds, or approximately HK$173 million, will be used for Phase II and Phase III clinical trials of TY-0540 as a monotherapy for platinum-resistant ovarian cancer; approximately 30% of the net proceeds, or approximately HK$86.53 million, will be used for Phase II and Phase III clinical trials of TY-0540 in combination with fulvestrant for CDK4/6-resistant breast cancer; and approximately 10% of the net proceeds, or approximately HK$28.84 million, will be used for working capital and general corporate purposes.

The equity investment demonstrates that the subscribers recognize the company's long-term growth potential. The proceeds from the subscription will provide the company with additional capital support and will be used for the company's overall business operations. The directors consider that the terms of the subscription are fair and reasonable and that the transactions contemplated thereunder are in the overall interests of the company and its shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment